DNCA Finance’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$34.7M Buy
28,936
+27,006
+1,399% +$27.6M 1.68% 17
2026
Q1
$1.78M Sell
1,930
-25
-1% -$25.3K 0.1% 72
2025
Q4
$2.1M Sell
1,955
-145
-7% -$139K 0.12% 68
2025
Q3
$1.6M Hold
2,100
0.11% 72
2025
Q2
$1.64M Sell
2,100
-6,100
-74% -$4.74M 0.13% 72
2025
Q1
$6.77M Sell
8,200
-922
-10% -$767K 0.56% 49
2024
Q4
$7.04M Sell
9,122
-291
-3% -$241K 0.55% 49
2024
Q3
$8.34M Sell
9,413
-11,274
-54% -$10.1M 0.71% 46
2024
Q2
$18.7M Buy
+20,687
New +$16.5M 1.61% 14

Other funds holding LLY

DNCA Finance's LLY Position: Q2 2026 in Review

DNCA Finance increased its Eli Lilly (LLY) stake by 1,399% in Q2 2026, buying an estimated $27.6M and bringing the position to 28,936 shares worth $34.7M. The position accounts for 1.68% of the portfolio, ranked #17.

DNCA Finance first reported a position in LLY in Q2 2024 and has held it in 9 quarters since. 4,626 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • DNCA Finance held 28,936 shares of Eli Lilly worth $34.7M as of Q2 2026.
  • DNCA Finance bought 27,006 Eli Lilly shares in Q2 2026, an estimated $27.6M.
  • Eli Lilly made up 1.68% of DNCA Finance's portfolio in Q2 2026, its #17 holding.
  • DNCA Finance first reported a position in Eli Lilly in Q2 2024 and has held it in 9 quarters since.
  • 4,626 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on DNCA Finance's 13F filing for Q2 2026, filed 13 Aug 2026.